Alterity Therapeutics ATH434 Slows MSA Decline by 52% in Phase 2 Trial
Alterity Therapeutics reported new Phase 2 analyses for its drug ATH434, showing that a 50 mg dosage significantly slowed functional decline by approximately 52% compared to a placebo over 52 weeks, as measured by the UMSARS scale. This result was adjusted for baseline levels of cerebrospinal fluid neurofilament light